ASCO 2017 | iFCG: a promising new regimen for treating IGHV-mutated CLL
Nitin Jain
• 2 Jun 2017
Nitin Jain, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, talks to us about the potential of iFCG, a combination of ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab in the treatment of chronic lymphocytic leukemia (CLL) with mutated IGHV gene and non-del(17p), as evaluated in a Phase II clinical trial (NCT02629809). He notes the positive results obtained from the trial, namely an increase in MRD negativity in patients, and hopes that this will translate to a better progression-free survival in these patients in the future. This interview was filmed at the American Society of Oncology (ASCO) 2017 Annual Meeting in Chicago, IL.
